CONTRATOS DE INVESTIGACIÓN. ART. 83
Contract
Evaluation of anti-CD160 antibodies in "in vivo" models.
Funder:
ELSALYS BIOTECH
date_range
Duration: from 11 March 2019 to 10 March 2020
(12 months)
Finished
euro
1,304.35 EUR
Of European scope.
Call:
(ELSALYS BIOTECH)
Researchers
Mª LUISA DEL
RÍO GONZÁLEZ
Leader
Publications related to the project
Show by yearArticle
-
Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression
2023
Frontiers in Immunology
-
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection
2022
Translational Research